Angiography

Diagnostic Imaging Services Market Size to Reach USD 67.94 Billion in 2030 | Emergen Research

Retrieved on: 
Monday, January 23, 2023
Safety, Merative, USD, Radiological Society of North America, Hospital, IBM, FDA, ASC, Radiology, MRI, Conditional sentence, Degenerative disc disease, Angiography, Sodium, Ultrasound, Death, Fatality, Surgeon, General Electric Company, Patient, Acquisition, Radiation exposure, Agfa-Gevaert, Communication, Vertebral compression fracture, Radiation, NCD, Vegetable, Annual general meeting, Prevalence, CT, Ionization, Shimadzu, Magnetic resonance imaging, Developed country, Diagnosis, Carestream Health, PET-CT, Non-communicable disease, Tobacco, CT scan, IBM Watson, Risk, Growth, World Health Organization, Google Images, RSNA, Neoplasm, Medical imaging

VANCOUVER, BC, Jan. 23, 2023 /PRNewswire/ -- The diagnostic imaging services market size reached USD 40.80 Billion in 2021 and is expected to register a CAGR of 5.8% during the forecast period, according to latest analysis by Emergen Research .

Key Points: 
  • VANCOUVER, BC, Jan. 23, 2023 /PRNewswire/ -- The diagnostic imaging services market size reached USD 40.80 Billion in 2021 and is expected to register a CAGR of 5.8% during the forecast period, according to latest analysis by Emergen Research .
  • Rising prevalence of chronic diseases, increasing elderly population, and rapid technological advancements in the healthcare diagnostic industry are some of the key factors boosting revenue growth of diagnostic imaging services market.
  • In addition, several product launches by key market players in diagnostic field are driving the growth of this market globally.
  • The diagnostic imaging services market is expected to register a CAGR of 5.8% over the forecast period and revenue is projected to increase from USD 40.80 in 2021 to USD 67.94 Billion in 2030.

Updated SCAI Guidance Includes Coronary IVL as a Treatment Option in All U.S. Catheterization Labs Regardless of Surgical Backup Status

Retrieved on: 
Tuesday, January 31, 2023
Consensus, Journal, IVL, Cardiovascular disease, Interventional cardiology, Hospital, Society, SCAI, Catheter, Intervention, Physician, Patient, FDA, Angiography, Calcium, Consultant, Health, Medical device

The latest guidance – SCAI Expert Consensus Statement on PCI Without On-Site Surgical Backup – was published online in the Journal of the Society of Cardiovascular Angiography and Intervention (JSCAI).

Key Points: 
  • The latest guidance – SCAI Expert Consensus Statement on PCI Without On-Site Surgical Backup – was published online in the Journal of the Society of Cardiovascular Angiography and Intervention (JSCAI).
  • The updated guidelines, which modify the previous 2014 guidelines by no longer restricting recommended treatment to facilities with on-site surgical backup, will now endorse expanded treatment options and access for patients with calcified coronary lesions.
  • “The previous guidelines required these patients in facilities without surgical backup be transferred interprocedurally via an ambulance to a cath lab with onsite surgical backup.
  • The 2014 guidelines recommended avoiding treatment of high-risk lesions defined as “more than moderate calcification” in facilities without surgical backup.

World’s First Intracranial Use of a New High-Frequency Imaging System to Directly Visualize Neurovascular Pathologies

Retrieved on: 
Thursday, January 12, 2023
Health, Technology, Neurology, Hospitals, Health Technology, Radiology, Artificial Intelligence, Pathology, X-ray, Brain, ST, ICAD, ABC, Angiography, Hospital, Research, AI, Aneurysm, Neuro, Conference, Health, Diagnosis, Radiology, Patient, Intravascular imaging, Stroke, Unity Health Toronto, El Equipo, Innovation, HF, Medical imaging, MD

Gentuity , LLC, an advanced imaging technology firm, today announced the first human use of the Vis-MTM High-Frequency Optical Coherence Tomography (HF-OCT) imaging system and probe.

Key Points: 
  • Gentuity , LLC, an advanced imaging technology firm, today announced the first human use of the Vis-MTM High-Frequency Optical Coherence Tomography (HF-OCT) imaging system and probe.
  • This represents a significant technological advance for the field of neurointervention, making high resolution intravascular imaging in the brain possible.
  • The direct visualization technology we evaluated here offers unprecedented potential in the diagnosis and treatment of aneurysms, stroke, intra-cranial atherosclerotic disease (ICAD) and other neurological pathologies,” said Vitor Mendes Pereira, MD.
  • “Revolutions in neurointerventional imaging, from the discovery of x-rays over 120 years ago, to 3-dimensional imaging in the angiography suite 20 years ago, occur roughly once in a generation.

Synchron Announces Publication of Brain-Computer Interface Clinical Trial in JAMA Neurology

Retrieved on: 
Monday, January 9, 2023
Biotechnology, Technology, Health, Biometrics, Wearables, Mobile Technology, Neurology, Health Technology, Medical Devices, Mobile, Wireless, Hardware, Clinical Trials, Clinical trial, Communication, Multiple sclerosis, Partnership, Salt Lake, Stroke, University, Muscle, Royal Melbourne Hospital, Neuroprosthetics, Paralysis, BCIS, Smartphone, Brain, Telephone, Multimedia, Carnegie Mellon University, Neurology, JAMA Neurology, BCI, Digital, Trial of the century, ALS, Acquisition, Angiography, Patient, Ripple, COMMAND, Learning, Safety, Motor cortex, Mount Sinai Hospital, SWITCH, Caregiver, Mobile phone, Management, Medical imaging, Journal of NeuroInterventional Surgery, Beckman Coulter

Synchron , an implantable brain-computer interface (BCI) company, today announced the medical journal JAMA Neurology has published peer-reviewed, long-term safety results from a clinical study in four patients with severe paralysis implanted with Synchron’s first-generation Stentrode™, a neuroprosthesis device.

Key Points: 
  • Synchron , an implantable brain-computer interface (BCI) company, today announced the medical journal JAMA Neurology has published peer-reviewed, long-term safety results from a clinical study in four patients with severe paralysis implanted with Synchron’s first-generation Stentrode™, a neuroprosthesis device.
  • Three out of six participants have been enrolled in the COMMAND trial, two in New York City and one in Pittsburgh.
  • For healthcare providers, patients, or caregivers interested in learning more about our ongoing US clinical trial, email: [email protected] .
  • A BCI could restore motor capability by using the cortical motor signal to bypass impaired limbs and directly control a computer.

Helios Technologies Appoints Lee Wichlacz to Newly Created Position as President of Electronics Segment

Retrieved on: 
Friday, December 9, 2022
Other Manufacturing, Electronic Design Automation, Automotive, Engineering, Technology, Automotive Manufacturing, General Automotive, Manufacturing, United Kingdom, CT, Software, Angiography, Marquette University, Cardiology, Agriculture, Cañada Region, NYSE, University of Wisconsin–Platteville, General Electric, Senior, Multimedia, Growth, University, Health, Mammography, Acquisition, Management, Helios, Electronics, Lincoln, Garland, Engineering

Helios Technologies, Inc. (NYSE: HLIO) (Helios or the Company), a global leader in highly engineered motion control and electronic controls technology for diverse end markets, announced today that Lee Wichlacz recently joined the Company and has been appointed to the newly created corporate officer position of President, Electronics, effective December 7, 2022.

Key Points: 
  • Helios Technologies, Inc. (NYSE: HLIO) (Helios or the Company), a global leader in highly engineered motion control and electronic controls technology for diverse end markets, announced today that Lee Wichlacz recently joined the Company and has been appointed to the newly created corporate officer position of President, Electronics, effective December 7, 2022.
  • Lee is a seasoned executive that brings both the depth of experience and discipline to help guide our Electronics segment as it grows into a billion-dollar business itself over time.
  • As we continue to grow both the segment as well as leverage our pure-play position at the intersection of hydraulics and electronics, Lee will be valuable in our efforts to advance our technologies and accelerate our growth.
  • Mr. Wichlacz was most recently the Group Vice President and General Manager - Americas, at Welbilt, Inc.

Global Radiation Dose Management Market to Reach $586.7 Million by 2032 - Exclusive DeepTech M-A-P™ Analysis by BIS Research

Retrieved on: 
Friday, December 16, 2022
Fujifilm, United Nations Scientific Committee on the Effects of Atomic Radiation, Degenerative disease, Benchmarking, Sectra AB, Canon Inc., UNSCEAR, Name, Software, Angiography, Center for Urban and Regional Analysis, Bayer, Research, Prevalence, Medtech, Patient safety, RDM, Radiation, Agfa-Gevaert, Radiation exposure, DMS, COVID-19, Annual report, General Electric Company, Radiology, Intermountain Healthcare, Risk, Medical imaging, Vaccine, Pharmaceutical industry, Guerbet

FREMONT, Calif., Dec. 16, 2022 /PRNewswire/ -- BIS Research, the global leader in providing market intelligence on deep technologies, has released its latest study titled Radiation Dose Management Market - A Global and Regional Analysis.

Key Points: 
  • FREMONT, Calif., Dec. 16, 2022 /PRNewswire/ -- BIS Research, the global leader in providing market intelligence on deep technologies, has released its latest study titled Radiation Dose Management Market -A Global and Regional Analysis.
  • According to this study, the global radiation dose management market was valued at $212.8 million in 2021 and is projected to reach $586.7 million by 2032.
  • Growing awareness and initiatives for radiation dose management are expected to push the adoption of dose management software.
  • Our strategic market analysis emphasizes on market estimations, technology analysis, emerging high-growth applications, deeply segmented granular country-level market data, and other important market parameters useful in the strategic decision-making for senior management.

Global Radiation Dose Management Market to Reach $586.7 Million by 2032 - Exclusive DeepTech M-A-P™ Analysis by BIS Research

Retrieved on: 
Friday, December 16, 2022
Fujifilm, United Nations Scientific Committee on the Effects of Atomic Radiation, Degenerative disease, Benchmarking, Sectra AB, Canon Inc., UNSCEAR, Name, Software, Angiography, Center for Urban and Regional Analysis, Bayer, Research, Prevalence, Medtech, Patient safety, RDM, Radiation, Agfa-Gevaert, Radiation exposure, DMS, COVID-19, Annual report, General Electric Company, Radiology, Intermountain Healthcare, Risk, Medical imaging, Vaccine, Pharmaceutical industry, Guerbet

FREMONT, Calif., Dec. 16, 2022 /PRNewswire/ -- BIS Research, the global leader in providing market intelligence on deep technologies, has released its latest study titled Radiation Dose Management Market - A Global and Regional Analysis.

Key Points: 
  • FREMONT, Calif., Dec. 16, 2022 /PRNewswire/ -- BIS Research, the global leader in providing market intelligence on deep technologies, has released its latest study titled Radiation Dose Management Market -A Global and Regional Analysis.
  • According to this study, the global radiation dose management market was valued at $212.8 million in 2021 and is projected to reach $586.7 million by 2032.
  • Growing awareness and initiatives for radiation dose management are expected to push the adoption of dose management software.
  • Our strategic market analysis emphasizes on market estimations, technology analysis, emerging high-growth applications, deeply segmented granular country-level market data, and other important market parameters useful in the strategic decision-making for senior management.

eMagin Corporation to Exhibit at FLORetina ICOOR 2022 Conference

Retrieved on: 
Thursday, December 1, 2022
Diagnosis, EMagin, OCT, Second International Congress on Education of the Deaf, Education, Ophthalmology, NYSE, Angiography, AR, Television, OLED

HOPEWELL JUNCTION, N.Y., Dec. 01, 2022 (GLOBE NEWSWIRE) -- eMagin Corporation (NYSE American: EMAN), a leader in the development, design, and manufacture of high-resolution OLED microdisplays for AR/VR and other near-eye imaging products, today announced its participation at FLORetina ICOOR 2022, the 10th International Congress on OCT and OCT Angiography, December 8-11, in Rome, Italy.

Key Points: 
  • HOPEWELL JUNCTION, N.Y., Dec. 01, 2022 (GLOBE NEWSWIRE) -- eMagin Corporation (NYSE American: EMAN), a leader in the development, design, and manufacture of high-resolution OLED microdisplays for AR/VR and other near-eye imaging products, today announced its participation at FLORetina ICOOR 2022, the 10th International Congress on OCT and OCT Angiography, December 8-11, in Rome, Italy.
  • For more information and to register for the conference, visit FLORetina.com
    eMagin will demonstrate OLED microdisplays suited for medical applications, including those used in ophthalmology applications like retinal surgery, imaging, diagnosis, and education.
  • eMagins displays offer high-contrast, wide color gamut, ultra-high resolution, and small form factors that are ideal for medical applications.
  • eMagin is the leader in OLED microdisplay technology, enabling the visualization of digital information and imagery for world-class customers in the military, consumer, medical and industrial markets.

Canon Medical Celebrates 30th Anniversary of Hybrid Angio-CT Technology with World’s First Deep Learning Spectral CT Reconstruction and HD 76 Technology Integration into Alphenix 4D CT System

Retrieved on: 
Monday, November 28, 2022
Doctor of Philosophy, Heart, Canon Medical Systems Corporation, Massachusetts General Hospital, Hospital, University, Trauma, Health care, RSNA, Safety, Trust, National Cancer Center, Health, Patient, FACC, Radiology, Radboud University Nijmegen, Intervention, Workflow, Life, Neurosurgery, Annual general meeting, Marketing, Senior, Hybrid, Cardiology, Molecular imaging, Iodine, Research, Deep learning, FNLA, Quality of life, MBBS, Spectral, Angiography, CT, CMSU, Medical imaging, MD

Pushing the capabilities of its Alphenix 4D CT system, CMSU announces the integration of the worlds first Deep Learning Spectral CT reconstruction and HD 76 high-definition imaging.

Key Points: 
  • Pushing the capabilities of its Alphenix 4D CT system, CMSU announces the integration of the worlds first Deep Learning Spectral CT reconstruction and HD 76 high-definition imaging.
  • Designed to take imaging capabilities to a whole new level, Deep Learning Spectral CT reconstruction offers automatically-generated monochromatic images, material-specific reconstruction, and iodine mapsrequiring no additional effort or training for technologists.
  • This provides a rich array of information to the interventional team within one room and by one system.
  • Deep Learning Spectral CT reconstruction is an upgrade option for Alphenix 4D CT customers with Aquilion ONE/Genesis Edition CT scanners.

The CorVista® Analysis Provides a Robust Prediction for Elevated Left Ventricular End Diastolic Pressure at the Point-Of-Care

Retrieved on: 
Thursday, November 17, 2022
Health, Communications, General Health, Research, Science, Cardiology, Publishing, Cardiovascular disease, FDA, Radiation, ML, Heart failure, Heart failure with preserved ejection fraction, Coronary artery disease, Injection, Exercise, Breakthrough, PLOS, AUC, Machine learning, Multimedia, Life expectancy, Limited, Pulmonary hypertension, Patient, Health equity, Publishing, Acquisition, Physician, Federal, Division, Degenerative disease, Commissioner of Food and Drugs, Angiography, Diagnosis, Cardiology, Fasting, Cardiac catheterization, Medical device, Medical imaging

This publication follows the recent achievement of the Breakthrough Designation from the FDA for the CorVista System to aid in the diagnosis of pulmonary hypertension.

Key Points: 
  • This publication follows the recent achievement of the Breakthrough Designation from the FDA for the CorVista System to aid in the diagnosis of pulmonary hypertension.
  • The measurements are used for the prediction of LVEDP, a key indicator of heart failure.
  • These data suggest a potential role for the novel CorVista System to predict of an elevated LVEDP at the point-of-care.
  • In doing so, the CorVista System is uniquely poised to advance the quality of care in rural and low-resource settings.